Equibles does not estimate personal net worth.
Get an email with a short summary when Milestone Pharmaceuticals Inc. publishes a filing, an earnings call transcript or a press release.
Get MIST alertsAmit Hasija is recorded as CFO at Milestone Pharmaceuticals Inc. (MIST). The newest filing on record that lists Amit Hasija as CFO at Milestone Pharmaceuticals Inc. (MIST) is dated April 30, 2026. The proxy statement of Milestone Pharmaceuticals Inc. reports total compensation of $991,905 for Amit Hasija in fiscal 2025, including a base salary of $472,770. Disclosed compensation is on record for 7 fiscal years. Amit Hasija has spoken on 3 earnings calls and 1 other investor event across 1 company, most recently for Milestone Pharmaceuticals Inc. on August 12, 2026. Milestone Pharmaceuticals Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Milestone Pharmaceuticals Inc. includes Joseph Oliveto (CEO and Board Member), Jeffrey Nelson (COO), David Sandoval (General Counsel) and 7 others.
“As of June 30, 2026, we had cash, cash equivalents, and short-term investments of $170.6 million. compared with $106 million at December 31st, 2025. We expect cash, cash equivalents, and short-term investments to be sufficient to cover operating expenses and capital expenditure into the second half of 2027.”
“We have a strong balance sheet, including approximately $184 million in cash, cash equivalents, and short-term investments as of March 31, 2026. This compares with $106 million at December 31, 2025.”
“That full-year revenue reflects a milestone earned under our License and Collaboration Agreement with CorkCell following FDA approval in the U.S. for Cardamist.”
“What I have up here now, you guys are probably used to, but you can look at this, our forward-looking statements on our website and review that at your leisure.”
Start not stated–present
Last confirmed April 30, 2026
Biotechnology · Healthcare
CFO
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Milestone Pharmaceuticals Inc. (MIST) | Chief Financial Officer and Executive Vice President of Corporate Development | $472,770 | $991,905 |
| 2024 | Milestone Pharmaceuticals Inc. (MIST) | Chief Financial Officer and Executive Vice President of Corporate Development | $437,750 | $601,517 |
| 2023 | Milestone Pharmaceuticals Inc. (MIST) | Chief Financial Officer and Executive Vice President of Corporate Development | $437,750 | $1,006,337 |
| 2022 | Milestone Pharmaceuticals Inc. (MIST) | Chief Financial Officer and Executive Vice President of Corporate Development | $425,000 | $1,324,579 |
| 2021 | Milestone Pharmaceuticals Inc. (MIST) | Chief Financial Officer and Executive Vice President of Corporate Development | $378,667 | $1,746,964 |
| 2020 | Milestone Pharmaceuticals Inc. (MIST) | Chief Financial Officer and Executive Vice President of Corporate Development | $353,333 | $1,992,732 |
| 2019 | Milestone Pharmaceuticals Inc. (MIST) | Chief Financial Officer and Executive Vice President of Corporate Development | $121,250 | $2,463,312 |
